Banco Santander(SAN) GlobeNewswire· Globenewswire·2025-06-09 05:00Core Viewpoint - Sanofi is proactively shipping Beyfortus (nirsevimab) to ensure availability ahead of the 2025-2026 RSV season, responding to increasing demand and aiming to support healthcare providers effectively [1][2]. Group 1: Product Availability and Production - Sanofi, in collaboration with AstraZeneca, has tripled production capacity and doubled manufacturing sites since Beyfortus's launch in 2023, with current supply matching last year's total doses distributed [2]. - Advance shipments of Beyfortus are being made to ensure broad availability for the upcoming RSV season, which typically runs from November to March [1]. Group 2: Efficacy and Impact - Beyfortus has shown high, sustained efficacy in protecting infants from RSV, supported by over 40 real-world studies involving 250,000 immunized infants [3]. - The duration of protection for Beyfortus has been extended to six months in the EU, allowing for season-long protection for all infants, including those immunized just before the RSV season [4]. Group 3: Market Context and Health Implications - RSV is highly contagious, infecting two out of three infants in their first year and nearly all children by their second birthday, making it a leading cause of hospitalization among infants worldwide [5]. - Beyfortus is distinguished as the longest-acting monoclonal antibody for RSV prevention, designed to protect all infants regardless of health conditions or timing of birth [6].